Inhaler Corticosteroid Device Market Report 2026

Inhaler Corticosteroid Device Market Overview

• Inhaler Corticosteroid Device market size has reached to $16.83 billion in 2025 • Expected to grow to $23.18 billion in 2030 at a compound annual growth rate (CAGR) of 6.6% • Growth Driver: Rising Prevalence Of Respiratory Diseases Fueling The Growth Of The Market Due To Increasing Air Pollution And Emergency Hospital Admissions • Market Trend: Innovative Dual-Action Rescue Inhalers Combining Albuterol And Budesonide Transform Asthma Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Inhaler Corticosteroid Device Market?

An inhaler corticosteroid device is a specialized medical tool designed to deliver anti-inflammatory corticosteroid medication directly into the lungs, where it works to reduce swelling and irritation in the airways caused by chronic respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). By targeting the lungs directly, these devices help manage and prevent symptoms such as wheezing, shortness of breath, and coughing, while minimizing systemic side effects that can occur with oral corticosteroids. The main types of products in inhaler corticosteroid devices are metered-dose inhalers, dry powder inhalers, and soft mist inhalers. Metered dose inhalers (MDIs) are handheld devices that deliver a specific, measured amount of medication to the lungs in the form of an aerosol. These devices contain various formulations, such as fluticasone propionate, budesonide, beclomethasone, and mometasone furoate, and are distributed through online pharmacies, retail pharmacies, direct sales, and hospital pharmacies. These devices serve a wide range of applications, including asthma, chronic obstructive pulmonary disease (COPD), and others, and are used by end users such as hospitals, home care, specialty clinics, and others.

What Is The Inhaler Corticosteroid Device Market Growth Forecast?

The inhaler corticosteroid device market size is expected to see strong growth in the next few years. It will grow to $23.18 billion in 2030 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to integration of ai and iot in inhaler devices, development of eco-friendly inhalers, expansion of telehealth services, personalized medication delivery, rising demand in emerging markets. Major trends in the forecast period include smart inhaler integration, personalized dosage management, telehealth-enabled monitoring, eco-friendly & sustainable device design, advanced aerosol delivery technologies.

Global Inhaler Corticosteroid Device Market Segmentation

1) By Product Type: Metered-Dose Inhalers, Dry Powder Inhalers, Soft Mist Inhalers 2) By Formulation Type: Fluticasone Propionate, Budesonide, Beclomethasone, Mometasone Furoate 3) By Distribution Channel: Online Pharmacies, Retail Pharmacies, Direct Sales, Hospital Pharmacies 4) By Application: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Other Applications 5) By End-User: Hospitals, Homecare, Specialty Clinics, Other End-Users Subsegments: 1) By Metered-Dose Inhalers: Conventional Metered-Dose Inhalers, Breath-Actuated Metered-Dose Inhalers, Spacer-Integrated Metered-Dose Inhalers 2) By Dry Powder Inhalers: Single-Dose Dry Powder Inhalers, Multi-Dose Dry Powder Inhalers, Reservoir Dry Powder Inhalers 3) By Soft Mist Inhalers: Manual Soft Mist Inhalers, Battery-Operated Soft Mist Inhalers

What Is The Driver Of The Inhaler Corticosteroid Device Market?

The increasing prevalence of respiratory diseases is expected to propel the growth of the inhaler corticosteroid device market going forward. Respiratory diseases refer to a range of conditions that affect the lungs and airways, making it difficult for individuals to breathe properly and efficiently. The prevalence of respiratory diseases is growing due to rising air pollution, which exposes individuals to harmful particles that damage lung tissue and trigger chronic conditions such as asthma and bronchitis. Inhaler corticosteroid devices are used to treat respiratory diseases by delivering anti-inflammatory medication directly to the lungs, helping to reduce inflammation and improve breathing. For instance, in June 2025, according to the Office for Health Improvement and Disparities, a UK-based government department, in the financial year ending 2024, England recorded 854,922 emergency hospital admissions for respiratory diseases, corresponding to a rate of 1,428 (ranging from 1,424 to 1,432) per 100,000 population, marking a 7% increase compared to the previous year. Therefore, the increasing prevalence of respiratory diseases is driving the growth of the inhaler corticosteroid device industry.

Key Players In The Global Inhaler Corticosteroid Device Market

Major companies operating in the inhaler corticosteroid device market are AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Teijin Pharma Limited, Sun Pharmaceutical Industries Limited, Aurobindo Pharma Limited, Chiesi Farmaceutici S.p.A., Cipla Limited, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals Inc., Mundipharma International Limited, Lupin Limited, Zydus Lifesciences Limited, Recipharm AB, Glenmark Pharmaceuticals Limited, Orion Corporation, Beximco Pharmaceuticals Limited, PARI Medical Holding GmbH

Global Inhaler Corticosteroid Device Market Trends and Insights

Major companies operating in the inhaler corticosteroid device market are focusing on introducing innovative solutions, such as rescue inhalers combining albuterol and budesonide to enhance treatment effectiveness and offer patients a more convenient, dual-action therapy in a single device. An inhaler combining albuterol and budesonide refers to a dual-action rescue inhaler that delivers both a bronchodilator (albuterol) to quickly open the airways and a corticosteroid (budesonide) to reduce inflammation, providing rapid symptom relief and long-term control of asthma in a single device. For instance, in January 2024, AstraZeneca PLC, a UK-based pharmaceutical industry company, launched AIRSUPRA, the first and only FDA-approved rescue inhaler combining albuterol and budesonide for adults with asthma. This inhaler is designed for as-needed use to both relieve acute bronchoconstriction symptoms and reduce airway inflammation, thereby lowering the risk of severe asthma exacerbations. It represents a novel approach by combining a short-acting beta2-agonist (albuterol) with an inhaled corticosteroid (budesonide) in a single inhaler, approved based on clinical trials demonstrating its superiority over albuterol alone in preventing asthma attacks.

What Are Latest Mergers And Acquisitions In The Inhaler Corticosteroid Device Market?

In May 2023, Phillips-Medisize Corporation, a U.S.-based medical technology and drug-delivery solutions company and a subsidiary of Molex LLC, acquired Vectura Group Ltd. for an undisclosed amount. With this acquisition, Phillips-Medisize Corporation aims to expand its inhaled drug-delivery portfolio, strengthen its end-to-end capabilities in inhalation device design and development, and accelerate innovation in combination products for pharmaceutical and biotech clients. Vectura Group Ltd. is a UK-based pharmaceutical company specializing in inhalation formulation, device development, and dry-powder inhaler technologies.

Regional Outlook

North America was the largest region in the inhaler corticosteroid device market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Inhaler Corticosteroid Device Market?

The inhaler corticosteroid device market consists of sales of nebulizer solutions, manual soft mist inhalers, conventional metered-dose inhalers, and combination inhalers. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.